Lymphoma Clinical Trial
Official title:
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Verified date | January 2014 |
Source | Children's Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase I clinical trial is studying the side effects and best dose of
imetelstat sodium in treating young patients with refractory or recurrent solid tumors or
lymphoma.
Status | Completed |
Enrollment | 34 |
Est. completion date | October 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year to 21 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of refractory or recurrent solid tumors, including lymphoma - No CNS tumors or known CNS metastases (Part A, dose escalation) - CNS tumors or known CNS metastases allowed (Part B, maximum-tolerated dose or recommended phase II dose) - No prior or concurrent CNS hemorrhage on a baseline MRI within the past 14 days - All patients must have histologic verification of malignancy at original diagnosis or relapse except for: - Intrinsic brain stem tumors - Optic pathway gliomas - Pineal tumors and elevations of CSF or serum tumor markers including alpha-fetoprotein or beta-HCG - Measurable or evaluable disease - Disease for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life - Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood count criteria and they are not known to be refractory to red cell or platelet transfusions PATIENT CHARACTERISTICS: - Karnofsky performance status (PS) 50-100% (patients > 16 years of age) OR Lansky PS 50-100% (patients = 16 years of age) - ANC = 1,000/mm³ - Platelet count = 100,000/mm³ (transfusion-independent, defined as not receiving platelet transfusion within the past 7 days prior to enrollment) - Creatinine clearance or radioisotope GFR = 70 mL/min OR a serum creatinine based on age and/or gender as follows: - 0.6 mg/dL (1 to < 2 years of age) - 0.8 mg/dL (2 to < 6 years of age) - 1.0 mg/dL (6 to < 10 years of age) - 1.2 mg/dL (10 to < 13 years of age) - 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age) - 1.7 mg/dL (male) or 1.4 mg/dL (female) (= 16 years of age) - Bilirubin (sum of conjugated and unconjugated) = 1.5 times upper limit of normal (ULN) - ALT = 110 U/L (ULN for ALT is 45 U/L) - Serum albumin = 2 g/dL - aPTT < 1.2 times ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use an effective contraception method - No uncontrolled infection - No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study PRIOR CONCURRENT THERAPY: - Recovered from acute toxic effects of all prior anti-cancer chemotherapy, immunotherapy, or radiotherapy - At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea) - At least 14 days since prior long-acting growth factor (e.g., Neulasta) or = 7 days since prior short-acting growth factor - At least 7 days since prior biologic or anti-neoplastic agent - At least 6 weeks since any type of prior immunotherapy (e.g., tumor vaccines) - At least 3 half-lives since last dose of a monoclonal antibody - At least 2 weeks since prior local palliative radiotherapy (small port) - At least 24 weeks since prior total-body irradiation, craniospinal radiotherapy, or radiation to = 50% of the pelvis - At least 6 weeks since prior substantial bone marrow radiation - At least 12 weeks since prior transplantation or stem cell infusion with no evidence of active graft vs host disease - Prior and concurrent stable or decreasing dose of corticosteroids within the past 7 days allowed - No prior allogeneic transplant - No other concurrent investigational drug - No other concurrent anticancer agents including chemotherapy, radiotherapy, immunotherapy, or biologic therapy - No concurrent cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post-bone marrow transplant or organ rejection post-transplant |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Hopital Sainte Justine | Montreal | Quebec |
Canada | Hospital for Sick Children | Toronto | Ontario |
United States | C.S. Mott Children's Hospital at University of Michigan Medical Center | Ann Arbor | Michigan |
United States | AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus | Atlanta | Georgia |
United States | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Bethesda | Maryland |
United States | UAB Comprehensive Cancer Center | Birmingham | Alabama |
United States | Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Children's Memorial Hospital - Chicago | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas | Dallas | Texas |
United States | Baylor University Medical Center - Houston | Houston | Texas |
United States | Riley's Children Cancer Center at Riley Hospital for Children | Indianapolis | Indiana |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Midwest Children's Cancer Center at Children's Hospital of Wisconsin | Milwaukee | Wisconsin |
United States | Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | New York | New York |
United States | Children's Hospital of Orange County | Orange | California |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania |
United States | Knight Cancer Institute at Oregon Health and Science University | Portland | Oregon |
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
United States | Children's Hospital and Regional Medical Center - Seattle | Seattle | Washington |
United States | Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St. Louis | Missouri |
United States | Children's National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Children's Oncology Group | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma | 21 Days | Yes | |
Primary | Toxicities of imetelstat sodium | Up to 30 days post-treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |